Condition: Advanced Solid Tumor · Metastatic Cancer · Cutaneous Melanoma · Sponsor: Aulos Bioscience, Inc.
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.
This description comes directly from the study's public registry record.
Jim Vasselli, MD · (707) 758-6776 · james@aulosbio.com
Always discuss trial participation with your own doctor first.
| Sylvester Comprehensive Cancer Center - Miami | Miami, Florida, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Minnesota Oncology and Hematology PA | Minneapolis, Minnesota, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Atlantic Healthcare System | Morristown, New Jersey, United States | Recruiting |
| Carolina Biooncology Institute | Huntersville, North Carolina, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| Texas Oncology (Balcones) - SCRI | Austin, Texas, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| START South Texas Accelerated Research Therapeutics | San Antonio, Texas, United States | Recruiting |
| University of Utah - Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
| Southside Cancer Care Centre | Miranda, New South Wales, Australia | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05267626